Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Employment test 11 - 50 employees
Company dna cabinet ores
operating since 1972
934.52
Headquarter in Paris
active in Legal Services, IP Consulting, and Matchmaking and Trading

We have observed 16 EP applications Dean Thomas has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after January 30, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12725512

AN ANTIOXIDANT COMPOSITION

IPC classification:
A61K 31/05, A61K 31/695, A61K 36/81, A61K 36/82, A61K 36/87
Agent:
Multiple attorneys, Cabinet Orès
Agent:
Gevers & Orès
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12735048

COMPOSITIONS FOR THE TREATMENT OF FRAGILE X SYNDROME

IPC classification:
A61K 31/404, A61P 25/00, A61P 25/28
Applicant:
Centre National de la Recherche Scientifique (CNRS)
Applicant:
Centre Hospitalier Régional d'Orléans
Applicant:
University of Orléans (Université d'Orléans)
Agent:
Multiple attorneys, Cabinet Orès
Agent:
Gevers & Orès
Status:
GRANT OF PATENT INTENDED
EP12715261

NEW TALE-PROTEIN SCAFFOLDS AND USES THEREOF

IPC classification:
A61K 38/16, C12N 9/22, C12N 15/10
Applicant:
Cellectis SA
Agent:
Santarelli
Agent:
Multiple attorneys, Cabinet Orès
Agent:
Gevers & Orès
Status:
GRANT OF PATENT INTENDED
EP11722878

METHOD TO INCREASE THE NUMBER OF DETECTABLE PHOTONS DURING THE IMAGING OF A BIOLOGICAL MARKER

IPC classification:
B82Y 15/00, G01N 21/64
Applicant:
Institut Pasteur
Agent:
Multiple attorneys, Cabinet Orès
Agent:
Gevers & Orès
Status:
PATENT GRANTED
EP10813011

SCREENING METHODS FOR IDENTIFYING PLASMODIUM PROTEASES INHIBITORS

IPC classification:
C12Q 1/37, G01N 33/569
Applicant:
Institut Pasteur
Agent:
Multiple attorneys, Cabinet Orès
Agent:
Gevers & Orès
Status:
GRANT OF PATENT INTENDED
EP12305248

De novo integron recombination sites and uses thereof

IPC classification:
C12N 15/74, C12N 15/90
Applicant:
Centre National de la Recherche Scientifique (CNRS)
Applicant:
Institut Pasteur
Agent:
Multiple attorneys, Cabinet Orès
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12816132

EXPRESSION CASSETTE

IPC classification:
C12N 15/09
Applicant:
Glenmark Pharmaceuticals SA
Agent:
Latscha Schöllhorn Partner AG
Agent:
Dean Thomas, Glenmark Pharmaceuticals SA
Status:
GRANT OF PATENT INTENDED
EP10719410

I-CREI VARIANTS WITH NEW SPECIFICITY AND METHODS OF THEIR GENERATION

IPC classification:
C12N 9/22, C12N 15/55, C12N 15/63, C12N 15/90
Applicant:
Cellectis SA
Agent:
Multiple attorneys, Cabinet Orès
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13808043

ANTI HER2 ANTIBODY FORMULATION

IPC classification:
A61K 39/395, C07K 16/32
Applicant:
Glenmark Pharmaceuticals SA
Agent:
Latscha Schöllhorn Partner AG
Agent:
Dean Thomas, Glenmark Pharmaceuticals SA
Status:
EXAMINATION IN PROGRESS
EP13811986

ANTIBODIES THAT BIND TO TL1A AND THEIR USES

IPC classification:
A61K 39/395, A61P 37/00, C07K 16/28
Applicant:
Glenmark Pharmaceuticals SA
Agent:
Latscha Schöllhorn Partner AG
Agent:
Dean Thomas, Glenmark Pharmaceuticals SA
Status:
EXAMINATION IN PROGRESS
EP14793557

PRODUCTION OF T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS

IPC classification:
B01D 15/38, C07K 16/46
Applicant:
Glenmark Pharmaceuticals SA
Agent:
Latscha Schöllhorn Partner AG
Agent:
Dean Thomas, Glenmark Pharmaceuticals SA
Status:
EXAMINATION REQUESTED
EP15707625

EXPRESSION CONSTRUCTS AND METHODS FOR SELECTING HOST CELLS EXPRESSING POLYPEPTIDES

IPC classification:
C12N 15/09
Applicant:
Glenmark Pharmaceuticals SA
Agent:
Latscha Schöllhorn Partner AG
Agent:
Dean Thomas, Glenmark Pharmaceuticals SA
Status:
EXAMINATION REQUESTED
EP15781677

ANTIBODIES THAT BIND TO CCR6 AND THEIR USES

IPC classification:
A61K 39/00, C07K 16/28
Applicant:
Glenmark Pharmaceuticals SA
Agent:
Latscha Schöllhorn Partner AG
Agent:
Dean Thomas, Glenmark Pharmaceuticals SA
Status:
Request for examination was made
EP15720336

T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS

IPC classification:
B01D 15/38, C07K 16/28, C07K 16/40, C07K 16/46
Applicant:
Glenmark Pharmaceuticals SA
Agent:
Latscha Schöllhorn Partner AG
Agent:
Dean Thomas, Glenmark Pharmaceuticals SA
Status:
Request for examination was made
EP15790129

CD3/CD38 T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS AND METHODS OF THEIR PRODUCTION

IPC classification:
A61K 39/395, C07K 16/28, C07K 16/46
Applicant:
Glenmark Pharmaceuticals SA
Agent:
Latscha Schöllhorn Partner AG
Agent:
Dean Thomas, Glenmark Pharmaceuticals SA
Status:
Request for examination was made
EP15807645

ANTI-TRKA ANTIBODIES WITH ENHANCED INHIBITORY PROPERTIES AND DERIVATIVES THEREOF FOR USE IN TREATING BONE ASSOCIATED PAIN

IPC classification:
A61K 39/395, A61P 29/00, C07K 16/28
Applicant:
Glenmark Pharmaceuticals SA
Agent:
Latscha Schöllhorn Partner AG
Agent:
Dean Thomas, Glenmark Pharmaceuticals SA
Status:
Request for examination was made

Please Sign in to use this feature